| Literature DB >> 23152869 |
Ruhong Cheng1, Ming Li, Hui Zhang, Yifeng Guo, Xilan Chen, Jianfeng Tao, Aifang Jiang, Jiecheng Gan, Huaishan Qi, Hong Yu, Wanqing Liao, Zhirong Yao.
Abstract
BACKGROUND: Filaggrin gene (FLG) mutations have been identified as the cause of ichthyosis vulgaris (IV) and major predisposing factors for atopic dermatitis (AD). The relationship among AD, IV and FLG mutations has not been clarified yet. Mutations 3321delA and K4671X, two of the most common mutations in Chinese patients, were both statistically associated with AD in case-control studies.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23152869 PMCID: PMC3496733 DOI: 10.1371/journal.pone.0049158
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Phenotype characteristics of 100 trios included in the analyses.
| Clinical information | Trios(n = 100) | |
| Parents(200) | Offspring(100) | |
| Han Chinese, n | 200 (100%) | 100 (100%) |
| Male sex, n | 100 (50%) | 66 (66%) |
| Mean±SD age, y | ND | 2.87±3.04 |
| Simple atopic dermatitis, n | 39 (19.5%) | 87 (87%) |
| Isolated ichthyosis vulgaris, n | 53 (26.5%) | – |
| atopic dermatitis + ichthyosis vulgaris, n | 29 (14.5%) | 13 (13%) |
| Keratosis pilaris, n | 44 (22%) | 4 (4%) |
| Palmar hyperlinearity, n | 72 (36%) | 31 (31%) |
| Cheilitis, n | 22 (11%) | 21 (21%) |
| Dyshidrosis, n | 53 (26.5%) | 8 (8%) |
| Mild atopic dermatitis (SCORAD,0–24points) | ND | 20 (20%) |
| Moderate atopic dermatitis (SCORAD,25–50points) | ND | 46 (46%) |
| Severe atopic dermatitis (SCORAD,51–103points) | ND | 34 (34%) |
Number affected/total number with data available.
SCORAD, SCORing atopic dermatitis.
ND, not done.
Frequencies of filaggrin gene null alleles in parents, offspring as well as normal controls.
| Genotype | 3321delA | K4671X | 3222del4 | Combined genotype | ||||||||
| parents | offspring | control | parents | offspring | control | Parents | offspring | control | parents | offspring | control | |
|
| 187(93.5%) | 89(89%) | 298(99%) | 182(91%) | 89(89%) | 293(97.3%) | 199(99.5%) | 99(99%) | 300(99.7%) | 169(85.0%) | 78(78%) | 289(96%) |
|
| 13(6.5%) | 10(10%) | 3(1.0%) | 18(9%) | 11(11%) | 8(2.7%) | 1(0.5%) | 1(1%) | 1(0.3%) | 30(14.5%) | 20(20%) | 12(3.9%) |
|
| 0 | 1(1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1(0.5%) | 2(2%) | 0 |
AA, Wild-type/wild-type/wild-type FLG genotype for 3321delA, 3222del4, and K4671X variants;
Aa, Heterozygous genotype for 3321delA, 3222del4 or K4671X;
aa, Homozygous 3321delA, K4671X or 3222del4 genotype or compound heterozygous genotype.
Figure 1Filaggrin gene mutation analysis and comparison of filaggrin expression.
The normal control was an FLG wt male adult. Patient 1 and 2 with K4671Xheter variant were mothers of 2 atopic dermatitis (AD) patients. Patient 3 was an adult male AD patient with K4671Xheter variant. Skin with normal appearance was got from the 4 subjects. (A) Identification of FLG mutations in 3 patients. Patient 1, 2, and 3 were all heterozygote for K4671X. (B) Quantitative Real-time reverse transcription–polymerase chain reaction analysis of FLG mRNA expression in the skin of normal control and 2 patients with K4671Xheter variant. Direct sequence analysis of FLG cDNA from mRNA expressed in skin samples further confirmed that Patient 2 and 3 were heterozygote for K4671X. FLG mRNA expression was not reduced either in Patient 2 or 3: FLG mRNA expression in Patient 2/3: FLG mRNA expression in control was1.26 and 3.25, respectively. (C) Immunohistochemical staining using antifilaggrin monoclonal antibody in 4 subjects at the same time (a,c,e,g,i: Original magnification×100; b,d,f,h,j:Original magnification×200). Immunohistochemically, it was obvious that filaggrin was strongly positive in the epidermis of Patient 1, 2, and 3(c–h).
Prevalance and comparison of compound genotype for common FLG mutations in various groups.
| Probands and controls | Compound genotype for common | |||
| n(n%) | P-value | OR | 95%CI | |
| control (301) | 12(3.99%) | – | – | – |
| All probands(100) | 22(22.00%) | <0.001 | 6.79 | 3.22–14.33 |
| Simple AD (87) | 14(16.09%) | <0.001 | 4.62 | 2.05–10.41 |
| AD with IV(13) | 8(61.50%) | <0.001 | 38.53 | 10.96–135.54 |
| AD from none-IV Family trios (40) | 2(5.00%) | >0.05 | – | – |
| AD from families with parental IV (60) | 20(33.33%) | <0.001 | 12.04 | 5.47–26.49 |
FLG, filaggrin gene; AD, atopic dermatitis; IV, ichthyosis vulgaris.
OR: odds ratio; CI : confidence interval;
Analysis of associations between combined common filaggrin gene mutations and atopic dermatitis associated phenotype.
| AD probands | Combined | ||
| AA | Aa/aa | P | |
| AD with IV | 5 | 8 | 0.001 |
| AD without IV | 73 | 14 | |
| AD with Palmar hyperlinearity | 16 | 15 | <0.001 |
| AD without Palmar hyperlinearity | 61 | 8 | |
| AD with Keratosis pilaris | 0 | 4 | 0.002 |
| AD without Keratosis pilaris | 78 | 18 | |
| AD with Dyshidrosis | 7 | 1 | 0.817 |
| AD without Dyshidrosis | 71 | 21 | |
| AD with Cheilitis | 14 | 7 | 0.265 |
| AD without Cheilitis | 64 | 15 | |
| AD with Infra-auricular and retroauricular fissuring | 20 | 3 | 0.237 |
| AD without Infra-auricular and retroauricular fissuring | 58 | 19 | |
FLG, filaggrin gene; AD, atopic dermatitis; IV, ichthyosis vulgaris.
Association analysis of filaggrin mutations with atopic dermatitis in both family and case-control studies.
| Results | 3321delA | K4671X | 3222del4 | |||
| Case-control | family | Case-control | family | Case-control | family | |
| P value | <0.001 | 0.003 | 0.002 | 0.815 | 0.437 | – |
| T:U | – | 12∶1 | – | 10∶8 | – | – |
| Odds Ratio | 12.28 | – | 4.53 | – | – | – |
| 95% CI | 3.35–44.98 | – | 1.77–11.60 | – | – | – |
| n%(100 probands) | 11.0% | – | 11.0% | – | 1.0% | – |
| n%(301 controls) | 1.0% | – | 2.7% | – | 0.3% | – |
P value represented as ratio of transmitted:untransmitted (T:U) filaggrin gene minor alleles;
CI : confidence interval.
Primer sequences for filaggrin and glyceraldehyde-3-phosphate dehydrogenase.
| Gene name | Primer sequence (5′ to3’) | Amplicon Size |
| h- |
| 126 bp |
| h- |
| |
| h- |
| 225 bp |
| h- |
|
FLG, filaggrin gene;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase gene.